# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Eva Perón (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML025-SYN
- Date: 2026-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucía Barragán, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Staging results and treatment decisions. **S**

## History of present illness

Ms. Perón returns two weeks after the diagnosis, in Spanish, to hear her staging results with Dr. Barragán and Dr. Osei-Bonsu, with the interpreter. She came alone by choice. She has thought about the fertility options and does not want to delay treatment for egg freezing or have an operation to move her ovaries; she understands that she will not be able to carry a pregnancy and that early menopause is likely, and is at peace with that decision. She has told a close friend and one colleague, and will tell her family herself. Bleeding is light, the pelvic ache is 3 of 10 with acetaminophen, and she has more energy since starting iron. Radiation planning was done three days ago. **S**

| Element | Detail |
|---|---|
| Staging | Pelvic MRI and PET-CT done; HIV and hepatitis C negative |
| Fertility decision | Declined egg freezing and ovarian transposition; does not want treatment delayed |
| Who knows | A friend and a colleague; she will tell her family herself |
| Symptoms | Light bleeding; pelvic ache 3 of 10; more energy |
| Scores | PHQ-9 8; GAD-7 7 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy; no fever or weight loss |
| Genitourinary | Positive | Light bleeding; no urinary symptoms |
| Musculoskeletal | Negative | No back pain or leg swelling |
| Psychiatric | Positive | Anxious about treatment but hopeful; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy **S**
- Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/68 mmHg; pulse 84 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 52.5 kg; BMI 19.3 kg/m². All vital signs are synthetic.

Hemoglobin: 10.2 g/dL (low); Mean cell volume: 77 fL (low); White cells: 6.8 10*3/uL; Platelets: 352 10*3/uL; Pelvic pain, worst in the past week (0 to 10): 3; PHQ-9: 8; GAD-7: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 9.4 g/dL (low) at baseline, 10.2 g/dL (low) at this visit **S**
- Mean cell volume: 72 fL (low) at baseline, 77 fL (low) at this visit **S**
- White cells: 7.1 10*3/uL at baseline, 6.8 10*3/uL at this visit **S**
- Platelets: 398 10*3/uL at baseline, 352 10*3/uL at this visit **S**
- Pelvic pain, worst in the past week (0 to 10): 4 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Less pale; pulse 84, blood pressure 110/68 |
| Abdomen | Soft; no mass |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Psychiatric | Calm and engaged; asks about the treatment schedule |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Squamous cell carcinoma of the cervix, FIGO 2018 stage IIB** (C53.9). Pelvic MRI shows a 4.6 by 4.1 cm cervical tumor with invasion of the left parametrium, not reaching the pelvic wall, involving only the upper vagina, without hydronephrosis, bladder or rectal invasion, or enlarged pelvic nodes. PET-CT shows intense uptake in the cervix and no uptake in pelvic or para-aortic nodes or elsewhere. HIV and hepatitis C tests are negative. FIGO 2018 stage IIB. The stage and what it means were explained to her in Spanish, with the plan: definitive chemoradiation with weekly cisplatin, then brachytherapy, aiming at cure, completed within eight weeks. She asked how likely cure is and was given an honest estimate that most women with this stage treated this way are alive and free of cancer years later, though not all. She agreed to treatment. Fertility decision recorded: she declined egg freezing and ovarian transposition. **S**
   - Pelvic external beam radiation 45 Gy in 25 fractions starting in one week, with cisplatin 40 mg/m2 weekly for five doses.
   - Image-guided brachytherapy after external beam, finishing within eight weeks of the start.
   - Weekly blood count, creatinine and magnesium on treatment.
   - Ondansetron for nausea and loperamide for diarrhea, to start with treatment.
   - No anti-inflammatory painkillers during cisplatin; acetaminophen only.
2. **Iron deficiency anemia** (D50.0). Hemoglobin 10.2 g/dL from 9.4 after three weeks of oral iron, a rise of 0.8 g/dL; now at the level wanted before radiation. **S**
   - Continue ferrous sulfate.
   - Hemoglobin checked weekly during treatment.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Disclosure and information preferences: she is told first, in Spanish, as much as she wants to know; she decides who else is told | Every visit | Completed today | Stage and likely outcome explained in Spanish; she chose to come alone and has told those she wished to |
| Imaging | Pelvic MRI | At staging, for local extent | Up to date | Six days ago: left parametrial invasion, no pelvic wall, upper vagina only, no hydronephrosis or nodes |
| Imaging | FDG PET-CT | At staging; about three months after chemoradiation | Up to date | Four days ago: cervix only; no nodal or distant uptake. Next about three months after treatment |
| Laboratory | HIV and hepatitis C tests | At diagnosis | Up to date | HIV and hepatitis C negative |
| Laboratory | Blood count (hemoglobin, white cells, platelets) | About one month after starting oral iron, then every three months for a year; weekly during chemoradiation | Completed today | Hemoglobin 10.2 g/dL, mean cell volume 77 fL, white cells 6.8, platelets 352 |
| Laboratory | Kidney function (creatinine, eGFR) and magnesium for cisplatin | Before cisplatin, weekly during it, and after | Up to date | Creatinine 0.7 mg/dL two weeks ago; weekly during cisplatin |
| Survey | Pelvic pain score and analgesic safety (no anti-inflammatory painkillers with cisplatin) | Every visit | Completed today | 3 of 10 on acetaminophen; no anti-inflammatory painkillers |
| Survey | PHQ-9 and GAD-7 | At diagnosis, before treatment, at mid-treatment, at the end of treatment, and in follow-up | Completed today | PHQ-9 8 (item 9 scored 0), GAD-7 7 |
| Referral | Fertility and ovarian function counseling and her decision | Before cancer treatment begins | Completed today | She declined egg freezing and ovarian transposition after counseling |
| Referral | Oncology social worker and spiritual care | At diagnosis and through treatment | Completed today | Social worker weekly during treatment; help with a reduced work schedule |

## Goal progress

- Diagnosis and stage explained to her directly, in Spanish, with time for questions, before any treatment decision. Outcome by 2026-03-02: Diagnosis given to her in person at the second visit and the stage at the third; she made the treatment and fertility decisions herself. **S**
- Hemoglobin 10 g/dL or more before radiation begins. Outcome by 2026-03-02: Hemoglobin 10.2 g/dL. **S**
- Chemoradiation and brachytherapy completed within eight weeks. In progress; target 2026-05-18. **S**
- No evidence of disease on PET-CT and examination three months after treatment. In progress; target 2026-08-17. **S**
- PHQ-9 below 5 by six months. In progress; target 2026-08-17. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027), National Comprehensive Cancer Network
- Revised FIGO staging for carcinoma of the cervix uteri (2018 (published 2019)), International Federation of Gynecology and Obstetrics (International Journal of Gynecology and Obstetrics)
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update (2018), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023), American Society of Clinical Oncology (Journal of Clinical Oncology)
- CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026), Aether Forge

## Follow-up

- Chemoradiation starts in one week, with weekly reviews by the oncology team. Review here two weeks after brachytherapy. **S**
- Next scheduled visit 2026-05-18: review two weeks after completing chemoradiation and brachytherapy: side effects, menopause symptoms, and survivorship care. **S**
